A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma
Abstract Osteosarcoma (OS), the most prevalent primary bone malignancy in adolescents, is typically treated with cisplatin‐based chemotherapy. However, the development of cisplatin resistance often leads to relapse or metastasis, significantly impairing therapeutic efficacy. To tackle this issue, pa...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , |
|---|---|
| Формат: | Статья |
| Язык: | английский |
| Опубликовано: |
Wiley
2025-07-01
|
| Серии: | Advanced Science |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1002/advs.202500632 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|